Caris provides artificial intelligence integrated molecular science technology that assesses deoxyribonucleic acid, Ribonucleic acid, and proteins to reveal a molecular blueprint that allows physicians and cancer patients to make personalized treatment decisions. It also researches and develops molecular profiling of blood and tissues. The company was founded in 2008 and is based in Irving, Texas.
Research containing Caris
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Caris in 4 CB Insights research briefs, most recently on Dec 20, 2022.
Expert Collections containing Caris
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Caris is included in 4 Expert Collections, including Unicorns- Billion Dollar Startups.
Unicorns- Billion Dollar Startups
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Precision Medicine Tech Market Map
This CB Insights Tech Market Map highlights 160 precision medicine companies that are addressing 9 distinct technology priorities that pharmaceutical companies and healthcare providers face.
This collection includes companies applying technology to cancer care, diagnosis, and treatment. Examples include vendors offering cancer detection and diagnosis, oncology clinical decision support, real-world data, and AI oncology drug discovery.
Caris has filed 1 patent.
Monoclonal antibodies, Molecular biology, Clusters of differentiation, Immunology, Biotechnology
Monoclonal antibodies, Molecular biology, Clusters of differentiation, Immunology, Biotechnology
Latest Caris News
Sep 12, 2023
The Caris Precision Oncology Alliance Welcomes Loyola University Chicago's Stritch School of Medicine News provided by Share this article Share toX Loyola University Chicago Stritch School of Medicine joins Caris' extensive network of leading cancer institutions and research consortia committed to improving patient outcomes through innovations in precision medicine IRVING, Texas, Sept. 12, 2023 /PRNewswire/ -- Caris Life Sciences ®(Caris), the leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition using molecular science and AI, announced today that Loyola University Chicago's Stritch School of Medicine has joined the Caris Precision Oncology Alliance™ (POA). The POA is a growing network of leading cancer centers and research consortia across the globe that collaborate to advance precision oncology and biomarker-driven research, with its members working together to establish and optimize standards of care for molecular testing through innovative research to improve clinical outcomes for cancer patients. POA members are uniquely positioned to leverage Caris' highly sophisticated AI bioinformatics and machine learning capabilities across the company's massive clinico-genomic database to enable innovative research to improve clinical outcomes for cancer patients. "This is an exciting moment to be in cancer research and our team of physician-scientists is glad to join the Caris Precision Oncology Alliance as it leads the way to improving the lives of people living with cancer," said William Small, Jr., M.D., chair, department of Radiation Oncology, Loyola Stritch School of Medicine and director, Cardinal Bernardin Cancer Center. "We're happy to welcome Loyola University and the Cardinal Bernadin Cancer Center into the growing Caris Precision Oncology Alliance network," said Chadi Nabhan , M.D., MBA, FACP, Chairman of the POA. "Our visions and goals are aligned in leveraging big data and precision oncology research to improve the outcomes of all patients diagnosed with cancer. We look forward to collaborating with physicians and researchers at Loyola University Chicago." The Caris Precision Oncology Alliance includes 89 cancer centers, academic institutions, research consortia and healthcare systems. These institutions have early access to the extensive database and artificial intelligence platform within Caris to establish evidence-based standards for cancer profiling and molecular testing in oncology. By leveraging the comprehensive genomic, transcriptomic and proteomic profiling available through Caris molecular profiling, Caris seeks to provide this network with the ability to prioritize therapeutic options and determine which clinical trial opportunities may benefit their patients. POA members are also able to integrate with a growing portfolio of biomarker-directed trials sponsored by biopharma. Additionally, POA member institutions have access to the most comprehensive clinico-genomic database in the industry, which includes matched molecular and clinical outcomes data from hundreds of thousands of cancer patients, covering over 1 million data points per patient. About Caris Life Sciences Caris Life Sciences® (Caris) is the leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition using molecular science and AI. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced artificial intelligence (AI) and machine learning algorithms, Caris has created the large-scale, clinico-genomic database and computing capability needed to analyze and unravel the molecular complexity of disease. This convergence of sequencing power, big data and AI technologies provides an unmatched platform to deliver the next-generation of precision medicine tools for early detection, diagnosis, monitoring, therapy selection and drug development. Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S., Europe, Asia and other international markets. To learn more, please visit CarisLifeSciences.com . About Loyola University Chicago Founded in 1870, Loyola University Chicago is one of the nation's largest Jesuit, Catholic universities, with more than 16,600 students (including nearly 11,500 undergraduates). The University has four campuses: three in the greater Chicago area and one in Rome, Italy and encompasses 14 schools, colleges, and institutes. Ranked a top national university by U.S. News & World Report, Loyola is among a select group of universities recognized for community service and engagement by prestigious national organizations like the Carnegie Foundation and the Corporation for National and Community Service. To learn more, visit LUC.edu . Learn more about Loyola's Stritch School of Medicine. Caris Life Sciences Media Contact: Lisa Burgner
Caris Frequently Asked Questions (FAQ)
When was Caris founded?
Caris was founded in 2008.
Where is Caris's headquarters?
Caris's headquarters is located at 750 W John Carpenter Fwy, Irving.
What is Caris's latest funding round?
Caris's latest funding round is Loan.
How much did Caris raise?
Caris raised a total of $1.714B.
Who are the investors of Caris?
Investors of Caris include OrbiMed Advisors, Braidwell, Sixth Street Partners, First Light Asset Management, Highland Capital Management and 15 more.
Who are Caris's competitors?
Competitors of Caris include Pangea Biomed and 4 more.
Compare Caris to Competitors
Tempus builds a library of molecular and clinical data as well as a corresponding operating system for data accessibility. The company enables physicians to deliver personalized cancer care for patients through analytical and machine-learning platforms. It provides genomic sequencing services and molecular therapeutic data analysis to empower physicians to make real-time, data-driven decisions. It serves clients in the healthcare sector. It was formerly known as Tempus Consulting. The company was founded in 2015 and is based in Chicago, Illinois.
Strata Oncology is a precision medicine company that provides no-cost tumor sequencing to advanced cancer patients and a portfolio of matching clinical trials.
DarwinHealth is a precision-focused cancer medicine company that has developed, owns, and utilizes proprietary algorithms and methodologies to match virtually every individual cancer patient – at every stage of their disease – with those drugs and drug combinations that are optimally suited to produce successful treatment outcomes.
Genialis builds software to empower scientists to find meaning in the data. Its platform operates a business-to-business (B2B) enterprise web software for high-throughput biological data management, analysis, visualization, and collaboration. The company was founded in 2015 and is based in Boston, Massachusetts.
GeneCentric focuses on the development and commercialization of molecular diagnostic assays that enable oncologists and patients to make more informed, individualized treatment decisions. GeneCentric was formerly known as GeneCentric Diagnostics. The company was founded in 2011 and is based in Durham, North Carolina.
BostonGene uses biomedical software for advanced patient analysis and personalized therapeutic decision-making in the fight against cancer. BostonGene's solution performs sophisticated analyses to assist physicians in evaluating viable treatment options for each patient's individual genetics, tumor microenvironment and tumor, clinical characteristics, and disease profile. BostonGene's seeks to enable physicians to provide all patients with the highest likelihood of survival through optimal cancer treatments using advanced and personalized therapies. The company was founded in 2015 and is based in Waltham, Massachusetts.